Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.52 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.50 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.44 |
| ▸ | KDM4A | O75164 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.44 |
| ▸ | TET3 | O43151 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630617 | 1.00 | FFAR4 (0.53) | FFAR4FFAR1PTPN1GPR84CAMK2A | |
| SCHEMBL15541850 | 0.98 | FFAR4 (0.57) | FFAR4FFAR1PTPN1GPR84CAMK2A | |
| SCHEMBL3337297 | 0.93 | PTPN1 (0.55) | FFAR4FFAR1PTPN1GPR84CAMK2A | |
| SCHEMBL31512908 | 0.89 | FFAR4 (0.57) | FFAR4FFAR1PTPN1GPR84CAMK2A | |
| SCHEMBL18955820 | 0.89 | FFAR1 (0.70) | FFAR4FFAR1PTPN1GPR84CAMK2A | |
| SCHEMBL6838371 | 0.89 | FFAR1 (0.70) | FFAR4FFAR1PTPN1GPR84CAMK2A | |
| SCHEMBL30497569 | 0.89 | FFAR1 (0.70) | FFAR4FFAR1PTPN1GPR84CAMK2A | |
| SCHEMBL19351243 | 0.89 | FFAR1 (0.70) | FFAR4FFAR1PTPN1GPR84CAMK2A | |
| SCHEMBL29123834 | 0.89 | FFAR1 (0.70) | FFAR4FFAR1PTPN1GPR84CAMK2A | |
| SCHEMBL30497568 | 0.89 | FFAR1 (0.70) | FFAR4FFAR1PTPN1GPR84CAMK2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753597-B1 | PROCESS FOR PURIFYING A STREAM COMPRISING 1,4-BUTANEDIOL | JOHNSON MATTHEY DAVY TECHNOLOGIES LTD (GB) | 2018-10-17 | — | — | EP | claimed |
| US-20140350308-A1 | Process For Purifying a Stream Comprising 1,4-Butanediol | JOHNSON MATTHEY DAVY TECHNOLOGIES LIMITED (GB) | 2014-11-27 | — | — | US | claimed |
| US-20120064611-A1 | Process For The Preparation of (3R)-Hydroxybutyl (3R) -Hydroxybutyrate By Enzymatic Enantioselective Reduction Employing Lactobacillus Brevis Alcohol Dehydrogenase | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2012-03-15 | — | — | US | claimed |
| EP-2419519-A1 | PROCESS FOR THE PREPARATION OF (3R)-HYDR0XYBUTYL (3R) -HYDROXYBUTYRATE BY ENZYMATIC ENANTIOSELECTIVE REDUCTION EMPLOYING LACTOBACILLUS BREVIS ALCOHOL DEHYDROGENASE | Isis Innovation Limited (GB) | 2012-02-22 | — | — | EP | claimed |
| US-20110237666-A1 | HYDROXYBUTYRATE ESTER AND MEDICAL USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2011-09-29 | — | — | US | claimed |
| US-12577591-B2 | Microorganisms and methods for increasing co-factors | GENOMATICA, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4662192-A1 | MICROORGANISMS AND METHODS FOR REDUCING BY-PRODUCTS | Genomatica, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250162967-A1 | PROCESS FOR PRODUCING A REFINED 1,4-BUTANEDIOL STREAM | JOHNSON MATTHEY DAVY TECHNOLOGIES LIMITED (GB) | 2025-05-22 | — | — | US | disclosed |
| WO-2024168072-A1 | MICROORGANISMS AND METHODS FOR REDUCING BY-PRODUCTS | GENOMATICA, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240150798-A1 | MICROORGANISMS AND METHODS FOR PRODUCING (3R)-HYDROXYBUTYL (3R)-HYDROXYBUTYRATE | GENOMATICA INC (US) | 2024-05-09 | — | — | US | disclosed |
| CN-117645586-A | Method and system for removing acetal through dehydration reaction in BDO refining process | 常州瑞华化工工程技术股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-11814664-B2 | Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate | GENOMATICA, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2013034881-A1 | PROCESS FOR PURIFYING A STREAM COMPRISING 1,4- BUTANEDIOL | DAVY PROCESS TECHNOLOGY LIMITED (GB) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013034881-A1 | PROCESS FOR PURIFYING A STREAM COMPRISING 1,4- BUTANEDIOL | DAVY PROCESS TECHNOLOGY LIMITED (GB) | 2013-03-14 | — | — | WO | disclosed |
| US-20120064611-A1 | Process For The Preparation of (3R)-Hydroxybutyl (3R) -Hydroxybutyrate By Enzymatic Enantioselective Reduction Employing Lactobacillus Brevis Alcohol Dehydrogenase | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| US-20120064611-A1 | Process For The Preparation of (3R)-Hydroxybutyl (3R) -Hydroxybutyrate By Enzymatic Enantioselective Reduction Employing Lactobacillus Brevis Alcohol Dehydrogenase | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2419519-A1 | PROCESS FOR THE PREPARATION OF (3R)-HYDR0XYBUTYL (3R) -HYDROXYBUTYRATE BY ENZYMATIC ENANTIOSELECTIVE REDUCTION EMPLOYING LACTOBACILLUS BREVIS ALCOHOL DEHYDROGENASE | Isis Innovation Limited (GB) | 2012-02-22 | — | — | EP | disclosed |
| EP-2419519-A1 | PROCESS FOR THE PREPARATION OF (3R)-HYDR0XYBUTYL (3R) -HYDROXYBUTYRATE BY ENZYMATIC ENANTIOSELECTIVE REDUCTION EMPLOYING LACTOBACILLUS BREVIS ALCOHOL DEHYDROGENASE | Isis Innovation Limited (GB) | 2012-02-22 | — | — | EP | disclosed |
| US-20110237666-A1 | HYDROXYBUTYRATE ESTER AND MEDICAL USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2011-09-29 | — | — | US | disclosed |
| US-20110237666-A1 | HYDROXYBUTYRATE ESTER AND MEDICAL USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064611-A1 | Process For The Preparation of (3R)-Hydroxybutyl (3R) -Hydroxybutyrate By Enzymatic Enantioselective Reduction Employing Lactobacillus Brevis Alcohol Dehydrogenase | ADH5, ADH1A, ADH1C | FFAR4 250/4885FFAR1 230/4885PTPN1 4835/4885 |
| US-20240150798-A1 | MICROORGANISMS AND METHODS FOR PRODUCING (3R)-HYDROXYBUTYL (3R)-HYDROXYBUTYRATE | ACACB, GRHPR, HSD17B10 | FFAR4 152/4885FFAR1 69/4885PTPN1 2450/4885 |
| US-20250162967-A1 | PROCESS FOR PRODUCING A REFINED 1,4-BUTANEDIOL STREAM | HSD17B7, ADH1C, SORD | FFAR4 1033/4885FFAR1 916/4885PTPN1 4237/4885 |
| US-20110237666-A1 | HYDROXYBUTYRATE ESTER AND MEDICAL USE THEREOF | FFAR3, FFAR1, PYGB | FFAR4 6/4885FFAR1 2/4885PTPN1 4852/4885 |
| US-11814664-B2 | Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate | ACACB, GRHPR, HSD17B10 | FFAR4 152/4885FFAR1 69/4885PTPN1 2450/4885 |
| US-12577591-B2 | Microorganisms and methods for increasing co-factors | ABAT, HADHB, MMAB | FFAR4 826/4885FFAR1 1076/4885PTPN1 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.